The above graphic indicates the diseases that we have treated with marrow
transplantation over the past 13 years. You can return to the program
page to learn more about each of these diseases. Marrow transplantation
is an exciting and developing field. New indices for this type of treatment
are continually being developed. The list of diseases which we treat is
never complete and we strive to expand it whenever the possibility arises.
Following is a listing of our current transplant protocols and their
perimeters. We also have a number of protocols we are using to investigate
such things as Aspergillus infection prevention, GvHD reduction/prevention,
treatment of severe GvHD, immune reconstitution, and treatment of EBV
post-organ transplant. Treatment decisions are always based upon an individual
patient's history, disease status, current health status, etc... We would
be happy to arrange a consultation with one
of our physicians to discuss an individual case. Please do not base your
treatment decisions or expectations on this list of protocols, it is intended
simply for reference.
|
Protocol
|
Diseases Treated
|
Notes
|
|
Dual cycle high-dose chemotherapy with peripheral blood stem cell
rescue for recurrent and progressive brain tumors.
|
Patient with recurrent or progressive brain tumors.
|
- Pediatric Blood and Marrow Transplant Consortium protocol.
- Evaluable disease is not required.
|
|
High dose thiotepa, VP-16, and cyclophosphamide with stem cell
rescue for pediatric patients with high risk, malignant solid tumors.
|
Patients with relapsed or high-risk solid tumors.
|
- Pediatric Blood and Marrow Transplant Consortium protocol.
- Must be in complete remission (CR) or very good partial remission
(VGPR is >90% tumor mass reduction).
|
|
Randomized trial of busulfan or total body irradiation conditioning
regimens for children with acute lymphoblastic leukemia.
|
Patients with ALL in 2nd or greater remission or in 1st remission
if high-risk.
|
- Pediatric Blood and Marrow Transplant Consortium protocol.
- Use of a related donor is required.
|
|
Bone Marrow and Peripheral Blood Stem Cell (Progenitor Cell) Transplantation/Infusion
in Pediatric Patients At the University of Iowa Hospitals and Clinics.
|
Any patient whose disease would benefit from BMT.
|
- Internal University of Iowa protocol.
- Intended to monitor the efficacy and complications of various
methods of autologous and allogeneic progenitor cell transplantation/infusion.
|
|
A pilot study of intensive chemotherapy with peripheral stem cell
support for infants with malignant brain tumors.
|
Patients with malignant brain or spinal cord tumors who have not
been treated previously.
|
- Children's Oncology Group protocol.
- Adequate stem cell collection for 3 rescues required.
|
|
Use of umbilical cord blood as a source of progenitor cells for
myeloablative therapy rescue (transplantation).
|
Patients in whom an allogeneic transplant is indicated.
|
- Internal protocol.
- UCB will be prioritized as a source of stem cell rescue only
if a related donor is not available and the patient would be at
risk while awaiting the identification and mobilization of an
unrelated donor.
|
